The mechanisms that lead to painful or insensate symptoms in diabetic neuropathy (DN) are poorly understood. Many variables likely play a role in the development of these diverse symptoms, including reduced neurotrophic supply, abnormal insulin support, and oxidative stress. These symptoms may also underlie peripheral axon damage amongst select sensory neuronal subpopulations. Our long-term goal is to understand the etiology of painful and/or insensate complications of DN in relation to insulin support, oxidative stress, and peripheral axon degeneration. The central hypothesis of this proposal is that unique genetic differences underlie the differential progression and severity of diabetic neuropathy. Exploring these genetic differences will help identify mechanisms involved in the pathogenesis of diabetic neuropathy.
Aim 1 will characterize the progression of painful and insensate neuropathy in type 1 (STZ- A/J vs. STZ-C57Bl/6) and type 2 (ob/ob vs. db/db) mouse models of diabetes and test whether neurotrophins can alleviate the diabetes-induced abnormalities in mechanical sensitivity.
Aim 2 will test whether insulin support plays a critical role in the progression of painful or insensate neuropathy amongst these variant mouse models of diabetes.
Aim 3 will examine the role of oxidative stress in the development of painful or insensate neuropathy in these diabetic mice.
Aim 4 will determine whether differential damage to epidermal axons is important factor in developing painful or insensate diabetic neuropathy. Collectively, these studies will identify three possible mechanisms responsible for the variable progression of symptoms experienced within human patients and identify new therapeutic targets aimed at the severity of symptoms amongst diabetic patients.
This proposal will elucidate mechanisms related to the development of painful versus nonpainful symptoms in mouse models of diabetic neuropathy. The role of neurotrophins, insulin support, oxidative stress, and axonal degeneration will be investigated to identify mechanisms that lead to the neural complications associated with diabetes.
|Cooper, Michael A; Kluding, Patricia M; Wright, Douglas E (2016) Emerging Relationships between Exercise, Sensory Nerves, and Neuropathic Pain. Front Neurosci 10:372|
|Katz, N K; Ryals, J M; Wright, D E (2015) Central or peripheral delivery of an adenosine A1 receptor agonist improves mechanical allodynia in a mouse model of painful diabetic neuropathy. Neuroscience 285:312-23|
|Groover, Anna L; Ryals, Janelle M; Guilford, Brianne L et al. (2013) Exercise-mediated improvements in painful neuropathy associated with prediabetes in mice. Pain 154:2658-67|
|Levant, Beth; Ozias, Marlies K; Guilford, Brianne L et al. (2013) Streptozotocin-induced diabetes partially attenuates the effects of a high-fat diet on liver and brain fatty acid composition in mice. Lipids 48:939-48|
|Grote, Caleb W; Ryals, Janelle M; Wright, Douglas E (2013) In vivo peripheral nervous system insulin signaling. J Peripher Nerv Syst 18:209-19|
|Guilford, B L; Wright, D E (2013) Chewing the fat: genetic approaches to model dyslipidemia-induced diabetic neuropathy in mice. Exp Neurol 248:504-8|
|Grote, Caleb W; Groover, Anna L; Ryals, Janelle M et al. (2013) Peripheral nervous system insulin resistance in ob/ob mice. Acta Neuropathol Commun 1:15|
|Jack, M M; Ryals, J M; Wright, D E (2012) Protection from diabetes-induced peripheral sensory neuropathy--a role for elevated glyoxalase I? Exp Neurol 234:62-9|
|Kluding, Patricia M; Pasnoor, Mamatha; Singh, Rupali et al. (2012) The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. J Diabetes Complications 26:424-9|
|Jack, Megan; Wright, Douglas (2012) Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Transl Res 159:355-65|
Showing the most recent 10 out of 27 publications